OAI-001 CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. O. Aboshady1, J. Raffa1, S. Quinney2, J. Tisdale1, B. Overholser1; 1College of Pharmacy, Purdue University, Indianapolis, IN, USA, 2School of Medicine, Indiana University, Indianapolis, IN, USA.
OAI-002 UTILIZING A MINIMAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC (MPBPK) MODEL FOR PREDICTING MATERNAL AND FETAL EXPOSURE TO MONOCLONAL ANTIBODIES DURING PREGNANCY. M. Kardouh1, J. Tiley2, T. Dunlap2, Y. Cao2; 1University of North Carolina at Chapel Hill and Certara, 2University of North Carolina at Chapel Hill.
OAI-003 UNDERSTANDING THE ASSOCIATIONS BETWEEN HIGH-DOSE METHOTREXATE PHARMACOKINETICS AND THE RISK OF TOXICITIES IN INFANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA. Z. Taylor1, T. Miller2, N. DeGroote3, S. Board4, E. Poweleit4, A. Chavana5, N. Ambrosino4, A. Weisnicht5, A. Brown5, B. Bernhardt6, E. Schafer5, M. O'Brien4, S. Castellino7, L. Ramsey8; 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, 2Department of Pediatrics, Emory University School of Medicine, 3Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, 4Cincinnati Children's Hospital Medical Center, 5Baylor College of Medicine, 6St. Jude's Children's Research Hospital, 7Emory Univ School of Medicine, 8Children's Mercy.
OAI-004 ORAL PROGESTERONE-MEDIATED ATTENUATION OF IBUTILIDE-INDUCED QT INTERVAL LENGTHENING IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN: POPULATION PHARMACOKINETIC/ PHARMACODYNAMIC MODEL. M. Yue1, J. Tisdale2, H. Jaynes3, B. Overholser2, K. Sowinski3, R. Kovacs4, M. Heathman5,6, S. Quinney7; 1Purdue University, West Lafayette, IN, United State, 2College of Pharmacy, Purdue University, Indianapolis, IN, USA, 3Purdue University, 4School of Medicine, Indiana University, 5Metrum Research Group, Tariffville, CT, US, 6School of Medicine, Indiana University, Indianapolis, IN, US, 7School of Medicine, Indiana University, Indianapolis, IN, USA.
